Advertisement
Table 4 Response to treatment over 28-day follow-up among participants with enrollment parasitemia <200,000 parasites/μL in a therapeutic efficacy study in Machinga, Nkhotakota, and Karonga Districts in Malawi, 2014 (n = 426)
| Estimate | AL | ASAQ | |||
|---|---|---|---|---|---|
| Total (n = 321) | Site | Total (n = 105) | |||
| Machinga (n = 112) | Nkhotakota (n = 104) | Karonga (n = 105) | |||
| Participants lost to follow-up, n (%) | 33 (10.3) | 14 (12.5) | 14 (13.5) | 5 (4.8) | 15 (14.3) |
| Treatment failure, n (%) | |||||
| Early | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Late* | 70 (24.3) | 22 (22.5) | 30 (33.3) | 18 (18) | 2 (2.2) |
| Day of failure, median (range) | 21 (14, 28) | 24.5 (14, 28) | 21 (14, 28) | 21 (14, 28) | 17.5 (14, 21) |
| Reinfection* | 68 (23.6) | 22 (22.5) | 30 (33.3) | 16 (16) | 1 (1.1) |
| Recrudescence | 2 (0.7) | 0 (0) | 0 (0) | 2 (2) | 1 (1.1) |
| Day 3 clearance, % (95 % CI)a | 99.7 (97.5–100) | 99.1 (94.5–100) | 100 (96.5–100) | 100 (96.6–100) | 100 (96.6–100) |
| ACPR, % (95 % CI)b | |||||
| Uncorrected | 75.7 (70–80.5) | 77.6 (68–83.4) | 67.7 (56–76.3) | 82 (73.1–89) | 97.8 (92.2–99.7) |
| PCR-corrected | 99.3 (97.5–99.9) | 100 (96.3–100) | 100 (96–100) | 98 (93–100) | 99 (94–100) |
| Kaplan–Meier survival rate on day 28, % (95 % CI)c | |||||
| Uncorrected | 76.3 (71.4–81.2) | 78.2 (70.2–86.3) | 67.4 (58–77.1) | 82.2 (74.8–89.7) | 97.9 (95–100) |
| PCR-corrected | 99.3 (98.3–100) | 100d | 100d | 97.9 (94.9–100) | 99.0 (96.9–100) |
